AdenotonsillectomyTiming-MidazolNCT07622641
Timing Of Midazolam İn Children Undergoing Adenotonsillectomy: Effects On Stress, Cortisol, And Recovery
A study testing Midazolam (Oral) and Midazolam (Intravenous) in people with Adenotonsillectomy and Preoperative Anxiety, run by Erzurum City Hospital at 1 site in Turkey (Türkiye).
Trial summary
This study is a prospective, randomized, controlled clinical trial designed to evaluate the optimal timing of midazolam administration in children undergoing adenotonsillectomy. The study will be conducted at the Departments of Otorhinolaryngology and Anesthesiology of Erzurum City Hospital. Read more about this study
- Who is it for?
- Ages 3 to 10 years
- Conditions the study is for
- Adenotonsillectomy, Preoperative Anxiety, Surgical Stress Response
- What is being tested?
- Midazolam (Oral) and Midazolam (Intravenous)
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Aug 2026to 1 Sep 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 10 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Children aged 3-10 years,
- Scheduled for elective adenoidectomy, tonsillectomy, or adenotonsillectomy,
- American Society of Anesthesiologists (ASA) physical status I-II,
- Written informed consent obtained from parents or legal guardians
Who cannot join
- Children younger than 3 years or older than 10 years,
- American Society of Anesthesiologists (ASA) physical status greater than II,
- Known allergy to apple or apple-derived products,
- Known allergy or hypersensitivity to benzodiazepines,
- Presence of developmental delay,
- History of neuropsychiatric disorders,
Show all 9Show fewer
- Current or recent use of corticosteroids,
- Expected or actual surgical duration longer than 90 minutes,
- Refusal of participation by parents or legal guardians
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Ahmet Ergün, MD contact
Turkey (Türkiye)1 site
Erzurum City Hospital
Erzurum, Yakutiye, 25240
Ahmet Ergün, MD
About this study
Official title: Optimization of Midazolam Administration Timing in Pediatric Adenotonsillectomy: Effects on Cortisol Response, Behavioral Stress, and Recovery Quality
This study is a prospective, randomized, controlled clinical trial designed to evaluate the optimal timing of midazolam administration in children undergoing adenotonsillectomy. The study will be conducted at the Departments of Otorhinolaryngology and Anesthesiology of Erzurum City Hospital.
Midazolam is commonly used in pediatric patients to reduce anxiety and improve perioperative comfort. However, the optimal timing of its administration (before surgery or during anesthesia induction) remains unclear. This study aims to compare the effects of preoperative oral midazolam and intraoperative intravenous midazolam on stress response, behavioral outcomes, and recovery quality.
Read more
Participants will be randomly assigned to one of two groups. In Group A, children will receive oral midazolam (0.5 mg/kg) 30 minutes before surgery. In Group B, children will receive intravenous midazolam (0.05-0.1 mg/kg) during anesthesia induction.
The primary outcome of the study is the change in serum cortisol levels, which reflects the physiological stress response. Blood samples will be collected twice: once 10 minutes after anesthesia induction and once 15 minutes after surgery in the post-anesthesia care unit.
In addition to cortisol levels, the study will assess preoperative anxiety using an observational anxiety scale, postoperative pain using a behavioral pain scoring system, and parental satisfaction using a standardized questionnaire. These measures aim to provide a comprehensive evaluation of the child's perioperative experience.
The findings of this study may help determine the most effective timing of midazolam administration to reduce stress, improve recovery, and enhance overall patient and family satisfaction in pediatric surgical care.
Read the detailed description
This study is a prospective, randomized, controlled clinical trial designed to evaluate the effects of the timing of midazolam administration on physiological stress response, behavioral anxiety, postoperative pain, recovery quality, and parental satisfaction in pediatric patients undergoing elective adenotonsillectomy.
The primary objective is to compare the effect of midazolam administration timing on physiological stress response, assessed by serum cortisol levels. Secondary objectives include evaluating preoperative anxiety levels, postoperative pain scores, recovery quality, and parental satisfaction between groups receiving midazolam at different time points.
The study will include children aged 3-10 years, classified as ASA physical status I-II, scheduled for elective adenoidectomy, tonsillectomy, or adenotonsillectomy.
Eligible patients will be identified during preoperative anesthesia evaluation. Parents or legal guardians will be informed about the study, and written informed consent will be obtained prior to enrollment.
Participants will be randomly assigned to one of two groups using a computer-generated randomization sequence with sealed envelope allocation:
Group A (Preoperative Midazolam Group): Patients will receive oral midazolam (0.5 mg/kg) 30 minutes before surgery, administered with a small volume of apple juice under clinical supervision.
Group B (Intraoperative Midazolam Group): Patients will receive intravenous midazolam (0.05-0.1 mg/kg) during anesthesia induction.
Anesthesia Protocol
To ensure comparability between groups, all patients will undergo a standardized anesthesia protocol. Vascular access will be established after inhalational induction using sevoflurane in oxygen, minimizing stress associated with intravenous cannulation.
Lidocaine (0.5-1 mg/kg) will be administered prior to propofol injection to reduce injection pain Propofol (2-3 mg/kg) will be used for induction Rocuronium (0.6 mg/kg) will be administered for neuromuscular blockade Fentanyl (1-2 µg/kg) will be used for analgesia
Anesthesia maintenance will be achieved with sevoflurane (2-3%) in a mixture of oxygen and air, targeting an age-adjusted MAC ≥1.3. Mechanical ventilation will be standardized with volume-controlled settings appropriate for age.
Intraoperative fluid management will be based on body weight using standard pediatric maintenance formulas and isotonic saline solution.
Neuromuscular blockade will be reversed with sugammadex (2 mg/kg) Extubation will be performed based on clinical recovery criteria, including adequate spontaneous respiration and responsiveness
All patients will receive intravenous paracetamol (10-15 mg/kg) for postoperative analgesia and ondansetron (0.1 mg/kg) for prophylaxis of nausea and vomiting.
Serum cortisol levels will be measured at two time points:
Intraoperative period (10 minutes after anesthesia induction) Early postoperative period (15 minutes after admission to the post-anesthesia care unit)
Cortisol levels will be analyzed using an electrochemiluminescence immunoassay method.
Preoperative anxiety will be assessed using a modified observational anxiety scale. Postoperative pain will be evaluated using a validated behavioral pain scoring system, and recovery status will be assessed using standard recovery criteria.
Parental satisfaction will be evaluated within the first 30 minutes after surgery using a structured questionnaire assessing overall perioperative experience.
All perioperative data will be recorded by the anesthesia team and post-anesthesia care unit staff. Collected data will be analyzed statistically to compare outcomes between the two groups.
- Being tested
- Midazolam (Oral), Midazolam (Intravenous)
- Keywords
- Midazolam, Pediatric Anesthesia, Adenotonsillectomy, Premedication Timing, Preoperative Anxiety, Cortisol Response, Postoperative Pain, Recovery Quality
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Midazolam (Oral)Drug
Oral midazolam will be administered at a dose of 0.5 mg/kg, 30 minutes before surgery. The medication will be mixed with a small volume of apple juice to facilitate administration.
Midazolam (Intravenous)Drug
Intravenous midazolam will be administered at a dose of 0.05-0.1 mg/kg during anesthesia induction.
| Study group | Role | What they receive |
|---|---|---|
| Preoperative Oral Midazolam | Experimental | Participants in this group will receive oral midazolam at a dose of 0.5 mg/kg, administered 30 minutes before surgery. The medication will be mixed with a small volume of apple juice to facilitate administration and improve tolerance. Receives: Drug: Midazolam (Oral) |
| Intraoperative Intravenous Midazolam | Experimental | Participants in this group will receive intravenous midazolam at a dose of 0.05-0.1 mg/kg during anesthesia induction. Receives: Drug: Midazolam (Intravenous) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Serum Cortisol Levels
Serum cortisol levels will be measured to assess physiological stress response.
Measured: At 10 minutes after anesthesia induction and at 15 minutes postoperatively in the post-anesthesia care unit (PACU)
Secondary outcomes (4)
Preoperative Anxiety Level (mYPAS Score)
Preoperative anxiety will be assessed using the modified Yale Preoperative Anxiety Scale (mYPAS), an observational tool evaluating behavioral anxiety in children across multiple domains. Scores will be normalized to a 0-100 scale, with higher scores indicating greater anxiety.
Measured: During the preoperative period before anesthesia induction
Postoperative Pain Score (FLACC Score)
Postoperative pain will be evaluated using the FLACC (Face, Legs, Activity, Cry, Consolability) scale, a validated behavioral pain assessment tool for pediatric patients. Each category is scored from 0 to 2, with a total score ranging from 0 to 10, where higher scores indicate more severe pain.
Measured: At 15 minutes postoperatively in the post-anesthesia care unit (PACU)
Recovery Status (Modified Aldrete Score)
Recovery status will be assessed using the Modified Aldrete Score, which evaluates activity, respiration, circulation, consciousness, and oxygen saturation. Higher scores indicate better recovery and readiness for discharge from the PACU.
Measured: Within the first 30 minutes postoperatively in the PACU
Parental Satisfaction (PAPS Survey)
Parental satisfaction will be evaluated using the Pediatric Anesthesia Parent Satisfaction (PAPS) survey, a structured questionnaire assessing satisfaction with perioperative care, including communication, pain management, and overall experience. Scores range from 5 to 25, with higher scores indicating greater satisfaction.
Measured: Within 30 minutes after the child becomes clinically stable in the postoperative period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2026
- Study start1 Aug 2026 (estimated)
- Primary completion1 Aug 2027 (estimated)
- Study completion1 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AdenotonsillectomyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned in a 1:1 ratio to one of two parallel groups based on the timing of midazolam administration (preoperative oral vs intraoperative intravenous). Randomization will be performed using a computer-generated sequence with sealed envelope allocation. Each participant will receive only one intervention, and outcomes will be compared between groups.
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Erzurum City Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mehmet Sercan Orbak, Erzurum City Hospital
- Investigators
- Mehmet Sercan Orbak, MD, Principal investigator, Erzurum City Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07622641
- Sponsor's protocol ID
- ECH-AR-MSO-02
- Acronym
- Timing-Midazol
- Status last verified
- Jun 2026
- First submitted
- 28 May 2026
- Last updated
- 10 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be publicly available due to institutional and ethical restrictions.